Climb Bio price target raised to $17 from $15 at Wedbush

Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform rating on the shares. With Climb Bio recently convening its R&D Spotlight event, the Q1 report was largely as expected, the firm notes. Most important, all key timelines were reiterated including near-term data in June for the CLYM116 /IgAN effort and budoprutug program in ITP.